Scinai Immunotherapeutics Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Amir Reichman
- Full Time Employees
- 31
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Jerusalem BioPark Building Jerusalem Israel
- IPO Date
- May 11, 2015
- CIK
- 0001611747
- Website
- scinai.com
- Similar Companies
- Business
- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is an Israel-based biopharmaceutical company focused on developing, manufacturing, and commercializing inflammation and immunology (I&I) biological products for autoimmune and infectious diseases; it also provides boutique contract development and manufacturing organization (CDMO) services through Scinai Bioservices. Founded in 2003 and headquartered at Jerusalem BioPark in Jerusalem, the company develops alpaca-derived nanosized VHH antibodies (nanoAbs) targeting diseases with large unmet needs such as psoriasis and asthma, developed in collaboration with Max Planck Institute for Multidisciplinary Sciences and University Medical Center Göttingen; it advances a focused nanoAb pipeline emphasizing high-value IL-17 programs with two STEP grant applications pending for up to €15 million each and actively pursues co-development or licensing partners; additionally, it offers the monoclonal antibody PC111 for pemphigus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Scinai Bioservices delivers end-to-end biologics solutions including molecule and clone selection, lab-scale development, CMC, upstream and downstream process development, scale-up, analytical methods development, bulk formulation, stability studies, regulatory documentation, tech transfer, sterile processes, aseptic filling for injectables in vials and syringes, and cGMP manufacturing compliant with FDA, EMA, and Israeli MoH standards for pre-clinical through Phase 3 trials, supported by a 1,850-square-meter state-of-the-art facility; the CDMO unit generates primary revenue, with Q1 2025 revenues nearly matching full-year 2024 levels, 2025 guidance of approximately $2 million, breakeven targeted by end-2026, and long-term potential of $12 million annually on a single shift. Recent developments include a March 2025 $10 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors enabling flexible capital raises, such as a $1.38 million drawdown in June 2025 at a 3% market discount without warrants; rapid CDMO revenue growth and capacity expansion; a targeted cost-reduction program lowering annual employment expenses by $815,000 to extend financial runway; an option agreement to acquire rare disease company PinCell and its antibody for severe dermatological conditions; a September 2023 rebranding from BiondVax Pharmaceuticals Ltd. to reflect its I&I and CDMO focus; and nine-month 2025 results highlighting continued CDMO momentum alongside nanoAbs pipeline advancements with grant decisions expected in Q1 2026.
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Up 2,371.8% in February
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Drop in Short Interest
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Up 3% – What’s Next?
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances
Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025